Skip to main content
. 2016 Apr 4;113(16):4470–4475. doi: 10.1073/pnas.1525349113

Fig. 6.

Fig. 6.

Inhibition of macrophage recruitment by CSF-1 blockade compromises the survival benefit of dual cediranib+MEDI3617 therapy. Mice bearing Gl261 tumors were treated with control (n = 16; solid green trace), anti–CSF-1 (αCSF-1; n = 18; dotted green trace), dual cediranib+MEDI3617 therapy (n = 28; solid blue trace), or anti–CSF-1 + dual therapy (n = 26; dotted blue trace). Anti–CSF-1 by itself had no effect on overall median survival compared with control treatment (7 d vs. 6 d). When combined with dual therapy, however, anti–CSF-1 significantly reduced overall median survival compared with dual therapy alone (10 d vs. 17 d; *P = 0.003). Dual therapy with or without combined anti–CSF-1 treatment significantly increased overall median survival compared with control treatment (P = 0.0035 and P < 0.0001, respectively). These data confirm the role of macrophages as essential mediators of the survival benefits observed with dual therapy.